Repligen (RGEN) | Stock Overview & Key Data
Repligen Performance Comparison
Stock Range
Today's Range
Low: $113.43
High: $118.99
on August 1, 2025
52 Week Range
Low: $102.97
High: $182.52
on April 7, 2025
on January 28, 2025
All-Time High: $327.32 on September 20, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$6.7B
EPS
-0.25
P/E Ratio (TTM)
511.11
Forward P/E
66.80
P/B Ratio
3.36
PEG Ratio
66.80
Div. Yield
N/A
ROE
-1.29%
Beta
1.114
Debt to Equity
34.44
Financial Highlights
Profitability
Gross Margin
53.65%
Operating Margin
6.36%
Profit Margin
-2.05%
Returns and Earnings
Return on Assets (TTM)
-0.90%
Return on Equity (TTM)
-1.29%
EBITDA
$47.6M
Net Income (TTM)
$-13.8M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$12.02
Quarterly Revenue Growth (YoY)
14.80%
Quarterly Earnings Growth (YoY)
160.20%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Repligen RGEN | 6.68B Mid-cap | -2.32% | -5.96% | -13.33% | -25.62% | -16.88% | -26.45% | -51.72% | -22.16% |
| Intuitive Surgical ISRG | 173.19B Large-cap | -2.57% | -10.20% | -6.59% | -16.49% | -7.81% | 7.42% | 101.03% | 111.32% |
| Becton, Dickinson BDX | 50.55B Large-cap | -4.83% | -0.73% | 4.03% | -28.77% | -22.13% | -27.08% | -30.63% | -29.50% |
| Align Technology ALGN | 9.90B Mid-cap | -33.59% | -29.73% | -22.76% | -36.74% | -34.52% | -36.05% | -53.55% | -55.36% |
| AptarGroup ATR | 9.33B Mid-cap | -12.20% | -11.11% | -4.67% | -9.38% | -8.31% | -2.98% | 33.79% | 18.53% |
| Avantor AVTR | 7.74B Mid-cap | -20.06% | -18.39% | -12.35% | -48.06% | -46.42% | -55.63% | -60.21% | -47.58% |
Ownership & Short Interest
Insider Ownership
6.40%
Institutional Ownership
105.27%
Shares Short
3M
Short Ratio
4.65
Short % of Shares Outstanding
8.16%
Average 10-Day Volume
1M
Average 90-Day Volume
893K
Repligen Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Repligen would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is RGEN's 52-week high and low?
- In the last 52 weeks, Repligen reached a high of $182.52 (on January 28, 2025) and a low of $102.97 (on April 7, 2025).
- What is the market cap and P/E ratio for RGEN?
- Curious about Repligen's size and valuation? Its market capitalization stands at 6.68B. When it comes to valuation, the P/E ratio (trailing twelve months) is 511.11, and the forward P/E (looking ahead) is 66.80.
- Does RGEN pay dividends? If so, what's the yield?
- As for dividends, Repligen isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Repligen's main competitors or similar companies to consider before investing?
When looking at Repligen, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Intuitive Surgical
ISRG173.19B Healthcare Medical Instruments & Supplies 7.42% 101.03% Becton, Dickinson
BDX50.55B Healthcare Medical Instruments & Supplies -27.08% -30.63% Align Technology
ALGN9.90B Healthcare Medical Instruments & Supplies -36.05% -53.55% AptarGroup
ATR9.33B Healthcare Medical Instruments & Supplies -2.98% 33.79% Avantor
AVTR7.74B Healthcare Medical Instruments & Supplies -55.63% -60.21% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Repligen Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Repligen's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -1.29%, the Debt to Equity ratio from the most recent quarter is 34.44, and its Gross Profit Margin stands at 53.65%.
- What is the recent revenue and earnings growth for RGEN?
- Looking at Repligen's growth, its revenue over the trailing twelve months (TTM) was $674M. Compared to the same quarter last year (YoY), quarterly revenue grew by 14.80%, and quarterly earnings saw a YoY growth of 160.20%.
- How much of RGEN stock is held by insiders and institutions?
- Wondering who owns Repligen stock? Company insiders (like executives and directors) hold about 6.40% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 105.27%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.